aTYR PHARMA (ATYR) Operating Margin (2019 - 2025)

aTYR PHARMA's (ATYR) quarterly Operating Margin came in at 14076.32% in Q3 2025, down 98.84% quarter-over-quarter from 7079.15% in Q1 2024.

Analysis

aTYR PHARMA (ATYR) Operating Margin (2019 - 2025) Analysis & Trends

aTYR PHARMA (ATYR) has reported Operating Margin for 6 consecutive years, with 14076.32% the latest figure, recorded in Q3 2025.

For the quarter ending Q3 2025, Operating Margin changed N/A year-over-year to 14076.32%; the trailing twelve-month figure through Mar 2026 stood at 38573.68% (changed N/A YoY), and the FY2025 full-year result was 40856.32%, down 1195674.0% from the prior year.
Operating Margin slipped to 14076.32% in Q3 2025 per ATYR's latest filing, from 7079.15% in the prior quarter.
Across five years, Operating Margin topped out at 76.55% in Q4 2022 and bottomed at 14076.32% in Q3 2025.
Historically, Operating Margin has averaged 6201.42% across 4 years, with a median of 5326.4% in 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Operating Margin (Qtr)
1	Amgen	208.48 Bn	194.49 Bn	7.24 Bn	34.95%
2	Gilead Sciences	186.29 Bn	183.02 Bn	6.22 Bn	-133.21%
3	Vertex Pharmaceuticals	128.79 Bn	120.93 Bn	2.84 Bn	37.40%
4	Regeneron Pharmaceuticals	80.66 Bn	72.67 Bn	3.93 Bn	30.15%
5	Moderna	61.46 Bn	56.32 Bn	52.00 Mn	-562.07%
6	Argenx Se	61.28 Bn	56.10 Bn	1.37 Bn	32.54%
7	Alnylam Pharmaceuticals	32.04 Bn	28.73 Bn	992.69 Mn	17.93%
8	Biogen	31.84 Bn	30.56 Bn	1.96 Bn	-23.56%
9	Roivant Sciences	28.74 Bn	29.43 Bn	1.16 Mn	-25,380.93%
10	aTYR PHARMA	35.31 Mn	-22.30 Mn	-	-

Historic Data

Download Data